BioAtla, Inc.

BioAtla is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for solid tumor cancers. The company's platform centers on conditionally active biologic (CAB) technology, which aims to enhance specificity and reduce off-target toxicity in cancer treatment. The company's lead candidates include mecbotamab vedotin for undifferentiated pleomorphic sarcoma and non-small cell lung cancer, and ozuriftabmab vedotin for melanoma and squamous cell carcinoma of the head and neck. Both are antibody-drug conjugates currently in clinical development.

The pipeline extends beyond these lead programs to include Evalstotug, a CAB anti-CTLA-4 antibody in development for multiple indications including melanoma and renal cell carcinoma, alongside earlier-stage candidates targeting various solid tumor types. These include BA3182, a bispecific candidate; BA3361, a Nectin-4 antibody-drug conjugate; and BA3142, a dual-CAB T-cell engager. The company also maintains preclinical programs combining CAB technology with checkpoint inhibitors and T-cell engagement approaches.

Based in San Diego, California, BioAtla operates with a small team of approximately 61 full-time employees. As a pre-revenue clinical-stage company, the organization is primarily focused on advancing its pipeline through clinical trials rather than generating commercial revenues. The company is incorporated in Delaware and trades on the Nasdaq.